HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Bupropion (Wellbutrin)

A unicyclic, aminoketone antidepressant. The mechanism of its therapeutic actions is not well understood, but it does appear to block dopamine uptake. The hydrochloride is available as an aid to smoking cessation treatment.

Also Known As:

Wellbutrin; Amfebutamone; (+-)-1-(3-Chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone; Bupropion Hydrochloride; Bupropion Hydrochloride, (+-)-Isomer; Bupropion, (+-)-Isomer; Esteve Brand of Bupropion Hydrochloride; Glaxo Wellcome Brand 1 of Bupropion Hydrochloride; Glaxo Wellcome Brand 2 of Bupropion Hydrochloride; Glaxo Wellcome Brand 3 of Bupropion Hydrochloride; GlaxoSmithKline Brand 1 of Bupropion Hydrochloride; GlaxoSmithKline Brand 2 of Bupropion Hydrochloride; Quomen; Zyban (Anti-Smoking); Zyntabac; 1-Propanone, 1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-

Networked: 1007 relevant articles (151 outcomes, 220 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 58
- Ketones: 431
  - Propiophenones
    - Bupropion: 1007

Experts

1.	Fava, Maurizio: 15 articles (08/2014 - 09/2002)
2.	Krishen, Alok: 12 articles (08/2010 - 01/2003)
3.	Rush, A John: 11 articles (03/2012 - 01/2005)
4.	Lerman, Caryn: 11 articles (06/2008 - 05/2004)
5.	Papakostas, George I: 10 articles (02/2014 - 03/2003)
6.	Ebbert, Jon O: 10 articles (01/2014 - 08/2002)
7.	Thase, Michael E: 10 articles (01/2014 - 01/2005)
8.	Modell, Jack G: 10 articles (08/2010 - 09/2002)
9.	Evins, A Eden: 9 articles (03/2015 - 03/2004)
10.	Trivedi, Madhukar H: 9 articles (11/2013 - 03/2006)

Related Diseases

1.	Tobacco Use Disorder (Nicotine Dependence) 02/01/2004 - "Bupropion SR has been shown to be effective for the treatment of nicotine dependence in adults. " 01/01/2002 - "Bupropion SR has also been found to be a useful treatment of tobacco dependence in various special populations of smokers who often experience difficulty in overcoming tobacco addiction. " 08/01/2015 - "Preclinical studies with bupropion in rodent models of nicotine dependence have generated equivocal findings with regard to translating the clinical efficacy of the antidepressant as a smoking cessation agent. " 01/01/2004 - "The aim of the study was a one year evaluation of the efficacy of bupropion SR supported by an educational program in the treatment of nicotine dependence and analysis of the reasons of relapses. " 01/28/2009 - "Ongoing studies continue to explore the behavioural and pharmacological effects of bupropion in smoking cessation studies and animal models of nicotine dependence. "
2.	Major Depressive Disorder (Major Depressive Disorders) 07/01/2007 - "In addition, neither CBTD nor bupropion, either alone or in combination, was differentially effective for smokers with single-past-episode major depressive disorder (MDD), recurrent MDD, or elevated depressive symptoms. " 01/01/2007 - "Safety and efficacy of bupropion extended release in treating a community sample of Hispanic and african american adults with major depressive disorder: an open-label study." 08/01/2004 - "This study evaluated the efficacy of bupropion for relapse prevention in smokers with and without a past history of major depressive disorder. " 05/01/2013 - "We investigated 532 tagging single nucleotide polymorphisms (SNPs) in 34 candidate genes for association with remission and response to either bupropion (n=319) or placebo (n=257) in patients with major depressive disorder. " 09/01/2013 - "An open-label, rater-blinded, 8-week trial of bupropion hydrochloride extended-release in patients with major depressive disorder with atypical features."
3.	Fatigue 10/01/2008 - "Bupropion sustained release may have psychostimulant-like effects and, therefore, may be beneficial in treating fatigue. " 01/01/2003 - "Bupropion SR demonstrated a significant reduction (p<.01, least square mean change) in symptoms over placebo on 4 domains (cognitive, retardation, fatigue/interest, and anxiety items)." 12/15/2006 - "There was also a greater improvement in fatigue scores among bupropion-treated (p < .0001) and SSRI-treated (p = .0005) than placebo-treated patients as well as a greater improvement in fatigue scores among bupropion-treated than SSRI-treated patients (p = .0078). " 11/01/2010 - "A repeat clinical evaluation conducted after 3 months of bupropion treatment indicated an improvement in fatigue (FSS score of 4) without changes in Beck Depression Inventory, Pittsburgh Sleep Quality Index, or Epworth Sleepiness Scale scores. " 02/01/2014 - "Bupropion treatment at the EU-approved dose of ≤300 mg/day may offer advantages over SSRIs in the resolution of sleepiness and fatigue in remitted MDD patients. "
4.	Weight Loss (Weight Reduction) 07/01/2002 - "To critically examine the efficacy of bupropion SR for weight loss. " 04/01/2013 - "The preliminary findings regarding short-term weight losses suggest the need for larger and longer-term trials to evaluate the potential utility of bupropion for enhancing outcomes of psychological interventions that have demonstrated effectiveness for BED but fail to produce weight loss. " 04/01/2007 - "Although originally developed as an antidepressant, long-term bupropion (BUP) treatment was recently shown to cause 5-8% weight loss over placebo in clinical trials with obese adults. " 07/01/2002 - "Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial." 09/01/2001 - "Subjects receiving bupropion achieved greater mean weight loss (last-observation-carried-forward analysis) over the first 8 weeks of the study (p = 0.0001): 4.9% +/- 3.4% (n = 25) for bupropion treatment compared with 1.3% +/- 2.4% (n = 25) for placebo treatment. "
5.	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 07/01/2007 - "Since attention-deficit/hyperactivity disorder (ADHD) is a well-documented risk factor for smoking and bupropion has been shown to be effective for smoking cessation, we tested the efficacy of bupropion as a prophylactic agent for the prevention of smoking in children and adolescents with ADHD. " 10/01/1996 - "This is a multisite, double-blind, placebo-controlled trial to determine the safety and efficacy of bupropion in the treatment of children with attention deficit disorder with hyperactivity (ADDH). " 12/01/2011 - "Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials." 04/01/2005 - "Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study." 08/01/1990 - "The authors treated 19 adults with attention-deficit hyperactivity disorder with an open trial of bupropion. "

Related Drugs and Biologics

1.	Nicotine
2.	varenicline (Chantix)
3.	Norepinephrine (Noradrenaline)
4.	Antidepressive Agents (Antidepressants)
5.	Dopamine (Intropin)
6.	Naltrexone (ReVia)
7.	venlafaxine (Effexor)
8.	Citalopram (Escitalopram)
9.	Sertraline (Zoloft)
10.	topiramate (Topamax)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Aftercare (After-Treatment)
3.	Injections
4.	Nebulizers and Vaporizers (Inhaler)
5.	Transdermal Patch